Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid-modifying effect and tolerability of MK-1903 in patients with dyslipidemia
2008-004555-30Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia comparing MK-1903 with Placebo (2 arms). Primary endpoints: Percent change from baseline in LDL-C at Day 29 and Percent change from baseline in HDL-C at Day 29. Started Dec 2008; status: completed.
02
Drugs
MK-1903
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on 2008-004555-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004555-30.